Next Article in Journal
Photochemically Aided Arteriovenous Fistula Creation to Accelerate Fistula Maturation
Next Article in Special Issue
Single-Cell RNA-Seq Identifies Pathways and Genes Contributing to the Hyperandrogenemia Associated with Polycystic Ovary Syndrome
Previous Article in Journal
Linderone Isolated from Lindera erythrocarpa Exerts Antioxidant and Anti-Neuroinflammatory Effects via NF-κB and Nrf2 Pathways in BV2 and HT22 Cells
Previous Article in Special Issue
Lovastatin, an Up-Regulator of Low-Density Lipoprotein Receptor, Enhances Follicular Development in Mouse Ovaries
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Local Immune Biomarker Expression Depending on the Uterine Microbiota in Patients with Idiopathic Infertility

by
Natalya I. Tapilskaya
,
Alevtina M. Savicheva
,
Kira V. Shalepo
,
Olga V. Budilovskaya
,
Aleksandr M. Gzgzyan
,
Olesya N. Bespalova
,
Tatiana A. Khusnutdinova
,
Anna A. Krysanova
,
Kseniia V. Obedkova
and
Galina Kh. Safarian
*
D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductive Medicine, 199034 St. Petersburg, Russia
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(8), 7572; https://doi.org/10.3390/ijms24087572
Submission received: 24 March 2023 / Revised: 18 April 2023 / Accepted: 18 April 2023 / Published: 20 April 2023
(This article belongs to the Special Issue Molecular Regulation in Female Reproduction 2.0)

Abstract

:
The endometrium has traditionally been considered sterile. Nowadays, active studies are performed on the female upper genital tract microbiota. Bacteria and/or viruses colonizing the endometrium are known to alter its functional properties, including receptivity and embryo implantation. Uterine cavity inflammation caused by microorganisms leads to disrupted cytokine expression, which, in turn, is mandatory for the successful implantation of the embryo. The present study assessed the vaginal and endometrial microbiota composition and its relation to the levels of cytokines produced by the endometrium in reproductive-aged women complaining of secondary infertility of unknown origin. The multiplex real-time PCR assay was applied for vaginal and endometrial microbiota analysis. The quantitative measurement of endometrial α-defensin (DEFa1), transforming growth factor (TGFβ1), and basic fibroblast growth factor (bFGF2) was carried out using the ELISA (Cloud-Clone Corporation (Katy, TX, USA; manufactured in Wuhan, China). A reliable decline in endometrial TGFβ1 and bFGF2 and an increase in DEFa1 were demonstrated in women with idiopathic infertility when compared to fertile patients. However, TGFβ1, bFGF2, and DEFa1 expression correlated reliably only with the presence of Peptostreptococcus spp. and HPV in the uterine cavity. The obtained results highlight the importance of local immune biomarker determination in the assessment of certain bacteria and viruses’ significance as causative agents of infertility.

1. Introduction

At present, there is evidence indicating the presence of endometrial microbiota [1]. The degree of uterine contamination depends on the qualitative and quantitative composition of microorganisms, as well as on the duration of colonization, determining the pattern of consecutive and possibly reversible events in endometrial function, including receptivity, blastocyst nesting, and desquamation during menstrual and/or menstrual-like bleeding [2]. However, which particular endometrial microorganisms and/or microbial associations exert the infectious agent’s role and their contribution in endometrial pathology remains unclear [3]. To date, scientific data has been accumulated on the potential negative impact of persistent endometrial microorganisms as a marker of chronic endometritis, the cause of recurrent implantation failure and spontaneous miscarriage [4].
In the review by Sirota et al. (2014), uterine cavity inflammation caused by the presence of bacteria was reported to alter the cytokine pathways necessary for successful blastocyst development and implantation [5]. An inflammatory cytokine reaction in endometriosis is known to significantly affect the reproductive outcome [6]. In addition, some pro-inflammatory cytokines, such as IL-6, and anti-inflammatory cytokines have been reported to be associated with various gynecological conditions, i.e., polycystic ovary syndrome (PCOS), tubal factor infertility, or infertility of unknown origin [7].
Defensins represent cationic peptides consisting of 18–45 amino acids, active against bacteria, fungi, and a large number of both enveloped and non-enveloped viruses [8]. These molecules play a key role in the body’s first-line protection against infectious agents [9]. More recently, the antiviral activity of some defensins was demonstrated [10]. Thus, the anti-HIV-1 activity of defensins was revealed, leading to growing opportunities in HIV investigation [11]. In addition, patients lacking α-defensins (specific granule deficiency syndrome) have increased susceptibility to bacterial infections [12].
The transforming growth factor beta (TGF-beta, TGFβ) represents a secreted extracellular multifunctional cytokine produced by all lines of white blood cells, controls an immense number of cellular responses, and participates in the development and homeostasis of most human body tissues [13]. The transforming growth factor beta gene (TGFB1 gene) maps to human chromosome 19. The regulation of inflammatory processes is believed to be one of the main functions of TGF-beta. In addition, this protein also plays a decisive role in stem cell differentiation, as well as T-cell regulation and differentiation [14]. TGFβ1 represents a polypeptide member of the transforming growth factor beta superfamily of cytokines and controls a number of cellular functions, including cell growth, proliferation, differentiation, and apoptosis. All the above-mentioned has a detrimental impact on the reproductive function of mammalians [15].
Fibroblast growth factor (FGF) is a representative growth factor that plays a crucial role in angiogenesis and early embryonic development in humans [16]. Until now, there is still no clear understanding of the impact of endometrial microbiota on antimicrobial peptides and cytokine expression. Thus, the present study aimed to assess the composition of vaginal and endometrial microbiota and its association with the levels of antimicrobial peptides and cytokines in endometrium samples of patients with infertility.

2. Results

2.1. Vaginal and Endometrial Microbiota Composition

In the infertile group of patients (n = 65), the endometrial microbiota analysis revealed a lack of microorganisms in 6 (9.23%) endometrial samples. Trichomonas vaginalis, Neisseria gonorrhoeae, Chlamydia trachomatis, HSV-1/2, CMV, EBV, and HHV-6 were not found in any endometrial samples.
Lactobacillus spp. (41.5%), Bacteroides spp., Porphyromonas spp., Prevotella spp. (38.8%), Gardnerella vaginalis (35.4%), Enterobacteriaceae spp. (18.5%), as well as Enterococcus spp. (16.9%) and Bifidobacterium spp. (16.9%) were most frequently identified endometrial microorganisms.
Megasphaera spp., Velionella spp., Peptostreptococcus spp., Sneathia spp./Leptotrihia spp./Fusobacterium spp., Enterobacteriaceae spp., Enterococcus spp., Candida spp. and Ureaplasma parvum were the most commonly verified combination of microorganisms.
Table 1 contains data on microbial concordance in both the endometrium and vagina. The highest microbiome concordance in the endometrium was demonstrated for Bifidobacterium spp. (36.8%), Gardnerella vaginalis (33.3%), Mycoplasma hominis (33.3%), Lactobacillus spp. (28.1%), Human papillomavirus (HPV) (26.7%), and Enterobacteriacea spp. (23.1%). Discordance in the endometrium microbiota was verified for Staphylococcus spp., Streptococcus agalactiae, Candida spp., Ureaplasma parvum, Trichomonas vaginalis, Haemophilus spp., and Anaerococcus spp.

2.2. Evaluation of Cytokines and α-Defensin in Endometrial Samples

A reliable decrease in endometrial TGFβ1 and bFGF2 concentrations in combination with increased DEFa1 concentration was demonstrated in the infertile group relative to the fertile group (Table 2).
The intragroup analysis of endometrial cytokines and α-defensin concentrations revealed their association with the history of recurrent herpes simplex virus (HSV) infection, ectopic pregnancy, and/or miscarriage. Table 3 contains data on cytokines and α-defensin concentrations in the endometrium samples of women with idiopathic infertility depending on microorganisms verified.

2.3. Patient Follow-Up

Eight (12.3%) cases of spontaneous pregnancy in the infertile group of patients were observed during the follow-up period. The retrospective analysis demonstrated reliably increased endometrial TGFβ1 (7.87 pg/mL [6568; 11.42]) and bFGF2 (36.4 pg/mL [28.3; 42.6]) concentrations. No significant differences were observed in levels of α-defensin. Table 4 represents the retrospectively determined data on endometrial microbiota composition in patients with achieved pregnancy.

3. Discussion

The implantation of an embryo for pregnancy initiation represents the most important stage in the onset of pregnancy and involves a process of superimposition of a blastocyst-derived signature onto the receptive endometrium during the mid-secretory phase of the menstrual cycle, the so-called “window of receptivity”. Both a receptive endometrium and timely signaling between the blastocyst and endometrium determine the success of implantation [17]. For instance, such endometrial factors as calcitonin [18], lysophosphatidic acid (LPA) [19], heparin-binding epidermal growth factor (HB-EGF) [20], leukemia-inhibiting factor (LIF) [21], and epidermal growth factor (EGF) [16] promote embryo implantation. At the same time, the endometrium undergoes remodeling in response to a variety of factors secreted by the embryo, i.e., hCG [6], IL-1 [15], BMP2 [18], IGF1 [20], FGF2 [16], and WNT [22]. The immune environment changes [19] and tissue remodeling [21] occurs at the contact site of the embryo with the uterine basal lamina.
Endometrial microbiota is known to play a significant role in pregnancy establishment [19]; however, the specification of the qualitative and quantitative composition of the resident endometrial microorganisms still requires the accumulation of scientific knowledge [2]. In our study, only 9.2% of the endometrium samples did not contain microorganisms, and only 29.2% of the subjects analyzed exerted 1 operational taxonomic unit. Further analysis revealed the most common taxa combination of Megasphaera spp./Velionella spp. with Peptostreptococcus spp. and Sneathia spp./Leptotrichia spp./Fusobacterium spp. Apparently, symbiotic microbial interactions ensure certain taxa combinations.
The highest concordance between the upper (endometrial) and lower (vaginal) microbiota was identified for Bifidobacterium spp./Gardnerella vaginalis (36.8%) and Bifidobacterium spp./Mycoplasma hominis (33.3%). In addition, high concordance was observed for Lactobacillus spp. (28.1%), HPV (26.7%), and Enterobacteriaceae (23.1%). The data obtained indicate a mainly ascending mode of upper genital tract seeding, such as migration of bacteria through the cervical canal. Previously, lower clinical pregnancy rates were demonstrated after bacteria were grown from the catheter tip after embryo transfer during the assisted reproductive technology procedure [23]. Swidsinski et al. (2013) demonstrated the presence of endometrial polymicrobial biofilms containing Gardnerella vaginalis in a fair number of women with bacterial vaginosis [24].
It should be emphasized that many receptivity biomarkers secreted by the endometrium and responsible for trophoblast invasion exist in two variants and the transition into the active variant is driven by hormonal, cytokine, and integrin signals from the implanting embryo [25,26]. For instance, human chorionic gonadotropin (hCG) is known to regulate the expression of four proteins in the human endometrium, namely, IL-11, CXCL10, GMCSF, and FGF2. It has been demonstrated that the FGF2 expression in the glandular epithelium of the human endometrium in vivo increases during the secretory phase of the menstrual cycle and remains high during the first trimester of pregnancy. FGF2 ensures the adhesion of trophectoderm to the inner cell mass (ICM) and type IV collagen [27].
The inducible bacteriolytic proteins (IBPs), represented by three proteins discovered in the giant silk moth Hyalophora cecropia, were first reported by D. Hultmark et al. in 1980 [28]. Five years later, T. Ganz et al. first described IBPs produced by human neutrophils, and the term “human defensin” was proposed [29]. At present, IBPs include human defensins, cathelicidins, and some other chemical groups implementing the antimicrobial potential of neutrophils and epithelial cells [30].
Human defensins are generally distinguished as arginine-, lysine-, histidine-, and cysteine-rich short peptides containing 28–51 amino acid residues. Six cysteine residues form one to three disulfide bonds promoting a three-dimensional molecular structure. The arrangement of disulfide bonds dictates the structural differences between defensins, generally divided into the alpha (α), beta (β), and theta (τ) subfamilies [31]. For instance, α-defensins consist of a triple-stranded β-sheet structure established by three disulfide bonds in positions Cys1-Cys6, Cys2-Cys4, and Cys3-Cys5 [9].
At least six human α-defensins are distinguished: four of them are primarily expressed in bone marrow cells, mainly promyelocytes, while two others are abundant in the small intestine’s Paneth cells. In addition, some amount of α-defensins is produced by epithelial cells providing a role in mucosal immunity. α-defensins are encoded by the HDEFA1 and HDEFA3 genes and their expression in neutrophils is proportional to the number of gene copies. In different populations the number of gene copies may vary, reaching a maximum of 12. α-defensins are known for the wide range of antimicrobial activity against both Gram-positive and Gram-negative bacteria such as Staphylococcus epidermidis, S. aureus, MRSA, E. coli, Salmonella typhimurium, Proteus mirabilis, P. vulgaris, Bacillus subtillis, Pseudomonas aeruginosa, Listeria monocytogenes, Burkholderia cepacia, Stenotrophomonas maltophilia, and Candida albicans, as some particular viruses [9].
According to the results of our study, a reliable decrease in endometrial TGFβ1 and bFGF2 and an increase in DEFa1 were demonstrated in women with idiopathic infertility when compared to fertile patients. However, TGFβ1, bFGF2, and DEFa1 expression correlated reliably only with the presence of Peptostreptococcus spp. and HPV in the endometrium. Additionally, the analysis of endometrial cytokines and α-defensin concentrations revealed their reliable correlation with the history of recurrent HSV infection, ectopic pregnancy, and/or miscarriage. These findings are possibly explained by inflammation-derived changes in functional properties of the endometrium during the periods of HSV exacerbation or surgical intervention for pregnancy termination.
Thus, at present, knowledge about endometrial microbiota’s significance in causing infertility of unknown origin is being actively developed. Bacteria and/or viruses persisting in the endometrium alter the functional properties of the latter, including its receptivity and embryo implantation [3]. Moreover, it is of high importance to determine the local immune biomarkers in the assessment of certain bacteria and viruses as causative agents of infertility [32], especially in women with recurrent HSV and HPV infection, a history of ectopic pregnancy, and miscarriage. Thus, it is of high relevance to continue further immune biomarker investigation and develop new therapeutic approaches, including not only antibacterial agents or acyclic nucleosides but also immunomodulating drugs.

4. Materials and Methods

4.1. General Study Design

The study was approved by the ethics committee of “The Research Institute of Obstetrics, Gynecology and Reproductive medicine named after D. O. Ott” (protocol code 108 dated 4 April 2021) and performed at the Department of Assisted Reproductive Technologies. The recruitment period of participants was from November 2019 to May 2022. All participants gave informed written consent for participation. A prospective analysis of the vaginal and uterine microbial composition was carried out. An enzyme-linked immunosorbent assay (ELISA) was performed to verify quantitative levels of α-defensin (DEFa1), the transforming growth factor β1 (TGFβ1), and basic fibroblast growth factor (bFGF2) (Cloud-Clone Corporation (Katy, TX, USA; manufactured in Wuhan, China)) in 65 reproductively-aged women (24 to 40 yo, with a mean age of 34 ± 3.8 years) complaining of secondary infertility in a one-year period. This cohort of patients represented the infertile group. The fertile group of patients included 14 age-matched potential surrogate women, undergoing a comprehensive gynecologic examination at the Department of Assisted Reproductive Technologies.
Inclusion criteria were the following: age 25–40 years old, confirmed secondary infertility despite regular sexual life, sexual partner’s age less than 50 years old, absence of antibacterial therapy in the past three months, and standard laboratory and clinical evaluation according to the order of the Russian Federation Ministry of Health. Exclusion criteria: age less than 25 years old or more than 40 years old, sexual partner’s age more than 50 years old, two or more sexual partners at the time, tubal, endocrine, male factors of infertility, any gynecologic pathology requiring surgical and/or hormonal treatment, diabetes mellitus or any other endocrine disease requiring hormonal replacement therapy, psychiatric disorders, alcohol and/or drug abuse, history of malignant tumors, HIV-positive patients including those on HAART, and history of viral hepatitis B or C.

4.2. Clinical and Social Characteristics of Patients Included

The clinical and social characteristics of patients recruited into the study are presented in Table 5.
Table 6 contains the obstetric and gynecological history of patients in the investigated groups.

4.3. Patients Investigation

All patients underwent serological detection of specific antibodies against HIV-1,2, Treponema pallidum, viral hepatitis B and C, as well as complete blood count.
During the gynecological examination, vaginal smears were obtained from all patients, separately from the posterior and lateral vaginal fornices. In order not to contaminate the endometrial microbiota with the vaginal one, an Endobrash Standard for Endometrial Cytology (Laboratorie C.C.D., France) was used for endometrial sampling. The latter represents a diamond-shaped brush for the removal of cells from the surface of the endometrium. It retracts completely into the sheath and is closed by a rounded end cap, ensuring the protection of the brush and the sample against contamination.

4.4. Sample Testing

For the purpose of DNA extraction, DNA-sorb-AM kits were used (“NextBio” LLC, Moscow, Russia) and DT-96 and DTPRIME amplifiers (“DNA-Technology” LLC, Moscow, Russia) were used for the reaction’s initiation.
A quantitative assessment of the total vaginal and endometrial bacterial mass was carried out using the multiplex Real-Time PCR Detection Kit (“DNA-Technology” LLC, Moscow, Russia). The implemented PCR method is based on the amplification of a target DNA sequence using one biological sample and is expressed in genomic equivalent (GE). GE, in turn, is defined as the amount of DNA necessary to be present in a purified sample to guarantee that all genes will be present. Upon completion of the run, a quantitative analysis of total bacterial mass and genius/species-specific DNA of Lactobacillus spp., Streptococcus spp., Streptococcus agalactiae, Staphylococcus spp., Gardnerella vaginalis, Atopobium vaginae, Anaerococcus spp., Bacteroides spp./Porphyromonas spp./Prevotella spp., Enrerococcus spp., Sneathia spp./Leptotrichia spp./Fusobacterium spp., Megasphaera spp./Veillonella spp./Dialister spp., Lachnobacterium spp./Clostridium spp., Peptostreptococcus spp., Bifidobacterium spp., Mobiluncus spp./Corynebacterium spp., Mycoplasma hominis, Ureaplasma urealyticum, Ureaplasma parvum, Candida spp., Candida albicans, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, and viruses (human herpes virus type 6 (HHV-6A), human cytomegalovirus (CMV), Epstein–Barr virus (EBV), herpes simplex virus type 1 and type 2 (HSV-1/HSV-2)) was obtained.
Human papilloma virus positivity was determined by the KVANT-21 kit (“DNA-Technology” LLC, Moscow, Russia) based on real-time PCR detection of oncogenic HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82) and non-oncogenic HPV types (6, 11, and 44). The viral load was expressed in absolute values reflecting the number of HPV DNA copies in the sample, and in relative values indicating the number of HPV DNA copies per human DNA.

4.5. Sample Testing

The quantitative measurement of endometrial DEFa1 (SEA124Hu), TGFβ1 (SEA124Hu), and bFGF2 (CEA551Hu) was carried out using a competitive inhibition enzyme immunoassay technique, Cloud-Clone Corporation (Katy, TX, USA; manufactured in Wuhan, China) according to the manufacturer’s instructions. First, the preparation of tissue homogenates was performed. Tissues were rinsed in ice-cold PBS to remove excess blood and minced into small pieces with a glass homogenizer on ice. The resulting suspension was sonicated with an ultrasonic cell disrupter. Then, the homogenates were centrifuged for 15 min at 1000× g. The obtained supernates were stored in aliquots at ≤−80 °C. The samples were brought to room temperature before performing the assay. Additionally, 20 μL of 1 M HCI was added to 100 μL of cell culture supernate for TGFβ1 detection. The concentration read of the standard curve was multiplied by the dilution factor—1.4. The optical density was measured at the wavelength of 450 ng/mL.
The standard curves with the log of DEFa1, TGFβ1, and bFGF2 concentrations on the y-axis and absorbance on the x-axis were created. The minimum detectable dose of TGFβ1 is typically less than 5.7 pg/mL, less than 4.43 pg/mL for bFGF2, and less than 0.125 pg/mL for DEFa1.

4.6. Patient Follow-Up

At least 12 months of follow-up counseling or a phone survey of recruited couples was carried out. In June 2022, the median follow-up period of patients was 18.6 months (ranging from 12.5 to 36.2 months).

Statistical Analysis

The present study is descriptive, not comparative. All statistical analyses were performed with STATISTICA 10.0 software. The Shapiro–Wilk test was used to evaluate the distribution of the parameters. Normally distributed measurement data were expressed as median (Me) and interquartile range (the difference between the 75th and 25th percentile). Data from the two groups were compared by the Mann–Whitney U test and Wilcoxon rank-sum test. For the prediction of possible outcomes of an uncertain event, the Monte Carlo test was applied. The microbiological concordance to a certain microorganism was estimated by the formula K = [a/a + b)] × 100%, where a is the number of patients testing positive for a specific microorganism both in the vagina and in the endometrium, and b is the number of patients testing positive for a specific microorganism either in the vagina or in the endometrium. Fisher’s exact test (χ2) test was used to compare the variables in cases of microorganism combination. For all tests, a p-value of <0.05 was considered statistically significant.

Author Contributions

Conceptualization, N.I.T. and A.M.S.; methodology, K.V.O. and A.M.G.; validation, O.N.B.; formal analysis, K.V.S.; investigation, O.V.B. and T.A.K.; writing—original draft preparation, A.A.K. and G.K.S.; writing—review and editing, A.M.G. and N.I.T.; funding acquisition, O.N.B. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Russian state budget assignment for the D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductive Medicine (1021062512052-5-3.2.2).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the ethics committee of the D.O. Ott Institute of Obstetrics, Gynecology, and Reproductive Medicine.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Moreno, I.; Garcia-Grau, I.; Perez-Villaroya, D.; Gonzalez-Monfort, M.; Bahçeci, M.; Barrionuevo, M.J.; Taguchi, S.; Puente, E.; Dimattina, M.; Lim, M.W.; et al. Endometrial microbiota composition is associated with reproductive outcome in infertile patients. Microbiome 2022, 10, 1. [Google Scholar] [CrossRef] [PubMed]
  2. Pirtea, P.; Cicinelli, E.; De Nola, R.; de Ziegler, D.; Ayoubi, J.M. Endometrial causes of recurrent pregnancy losses: Endometriosis, adenomyosis, and chronic endometritis. Fertil. Steril. 2021, 115, 546–560. [Google Scholar] [CrossRef] [PubMed]
  3. Tapilskaya, N.I.; Budilovskaya, O.V.; Krysanova, A.A.; Tolibova, G.K.; Kopylova, A.A.; Tsypurdeeva, N.D.; Gzgzyan, A.M.; Savicheva, A.M.; Kogan, I.Y. Endometrial microbiota of women with chronic endometritis and idiopathic infertility. Akusherstvo I Ginekol. 2020, 4, 72–81. [Google Scholar] [CrossRef]
  4. Espinós, J.J.; Fabregues, F.; Fontes, J.; García-Velasco, J.A.; Llácer, J.; Requena, A.; Checa, M.Á.; Bellver, J.; Spanish Infertility SWOT Group (SISG). Impact of chronic endometritis in infertility: A SWOT analysis. Reprod. Biomed. Online 2021, 42, 939–951. [Google Scholar] [CrossRef] [PubMed]
  5. Sirota, I.; Zarek, S.M.; Segars, J.H. Potential influence of the microbiome on infertility and assisted reproductive technology. Semin. Reprod. Med. 2014, 32, 35–42. [Google Scholar] [CrossRef]
  6. Robertson, S.A.; Moldenhauer, L.M.; Green, E.S.; Care, A.S.; Hull, M.L. Immune determinants of endometrial receptivity: A biological perspective. Fertil. Steril. 2022, 117, 1107–1120. [Google Scholar] [CrossRef]
  7. Tortorella, C.; Piazzolla, G.; Matteo, M.; Pinto, V.; Tinelli, R.; Sabbà, C.; Fanelli, M.; Cicinelli, E. Interleukin-6, interleukin-1β, and tumor necrosis factor α in menstrual effluents as biomarkers of chronic endometritis. Fertil. Steril. 2014, 101, 242–247. [Google Scholar] [CrossRef]
  8. Gao, X.; Ding, J.; Liao, C.; Xu, J.; Liu, X.; Lu, W. Defensins: The natural peptide antibiotic. Adv. Drug. Deliv. Rev. 2021, 179, 114008. [Google Scholar] [CrossRef]
  9. Zhai, Y.J.; Feng, Y.; Ma, X.; Ma, F. Defensins: Defenders of human reproductive health. Hum. Reprod. Update 2023, 29, 126–154. [Google Scholar] [CrossRef]
  10. Park, M.S.; Kim, J.I.; Lee, I.; Park, S.; Bae, J.Y.; Park, M.S. Towards the Application of Human Defensins as Antivirals. Biomol. Ther. 2018, 26, 242–254. [Google Scholar] [CrossRef]
  11. Pace, B.T.; Lackner, A.A.; Porter, E.; Pahar, B. The role of defensins in HIV pathogenesis. Mediators Inflamm. 2017, 2017, 5186904. [Google Scholar] [CrossRef] [PubMed]
  12. Shigemura, T.; Yamazaki, T.; Shiohara, M.; Kobayashi, N.; Naganuma, K.; Koike, K.; Agematsu, K. Clinical course in a patient with neutrophil-specific granule deficiency and rapid detection of neutrophil granules as a screening test. J. Clin. Immunol. 2014, 34, 780–783. [Google Scholar] [CrossRef] [PubMed]
  13. Xu, X.; Zheng, L.; Yuan, Q.; Zhen, G.; Crane, J.L.; Zhou, X.; Cao, X. Transforming growth factor-β in stem cells and tissue homeostasis. Bone Res. 2018, 6, 2. [Google Scholar] [CrossRef]
  14. Yang, D.; Dai, F.; Yuan, M.; Zheng, Y.; Liu, S.; Deng, Z.; Tan, W.; Chen, L.; Zhang, Q.; Zhao, X.; et al. Role of Transforming Growth Factor-β1 in Regulating Fetal-Maternal Immune Tolerance in Normal and Pathological Pregnancy. Front. Immunol. 2021, 12, 689181. [Google Scholar] [CrossRef] [PubMed]
  15. Kumar, V.; Maurya, V.K.; Joshi, A.; Meeran, S.M.; Jha, R.K. Integrin Beta 8 (ITGB8) Regulates Embryo Implantation Potentially via Controlling the Activity of TGF-B1 in Mice. Biol. Reprod. 2015, 92, 1–17. [Google Scholar] [CrossRef] [PubMed]
  16. Wollenhaupt, K.; Welter, H.; Einspanier, R.; Manabe, N.; Brüssow, K.P. Expression of epidermal growth factor receptor (EGF-R), vascular endothelial growth factor receptor (VEGF-R) and fibroblast growth factor receptor (FGF-R) systems in porcine oviduct and endometrium during the time of implantation. J. Reprod. Dev. 2004, 50, 269–278. [Google Scholar] [CrossRef] [PubMed]
  17. Parrilla, I.; Gil, M.A.; Cuello, C.; Cambra, J.M.; Gonzalez-Plaza, A.; Lucas, X.; Vazquez, J.L.; Vazquez, J.M.; Rodriguez-Martinez, H.; Martinez, E.A. Immunological uterine response to pig embryos before and during implantation. Reprod. Domest. Anim. 2022, 57, 4–13. [Google Scholar] [CrossRef]
  18. Pantos, K.; Grigoriadis, S.; Maziotis, E.; Pistola, K.; Xystra, P.; Pantou, A.; Kokkali, G.; Pappas, A.; Lambropoulou, M.; Sfakianoudis, K.; et al. The Role of interleukins in recurrent implantation failure: A comprehensive review of the literature. Int. J. Mol. Sci. 2022, 23, 2198. [Google Scholar] [CrossRef]
  19. Inversetti, A.; Zambella, E.; Guarano, A.; Dell’Avanzo, M.; Di Simone, N. Endometrial microbiota and immune tolerance in pregnancy. Int. J. Mol. Sci. 2023, 24, 2995. [Google Scholar] [CrossRef]
  20. Yoshihara, M.; Mizutani, S.; Kato, Y.; Matsumoto, K.; Mizutani, E.; Mizutani, H.; Fujimoto, H.; Osuka, S.; Kajiyama, H. Recent insights into human endometrial peptidases in blastocyst implantation via shedding of microvesicles. Int. J. Mol. Sci. 2021, 22, 13479. [Google Scholar] [CrossRef]
  21. Governini, L.; Luongo, F.P.; Haxhiu, A.; Piomboni, P.; Luddi, A. Main actors behind the endometrial receptivity and successful implantation. Tissue Cell. 2021, 73, 101656. [Google Scholar] [CrossRef] [PubMed]
  22. Whitby, S.; Zhou, W.; Dimitriadis, E. Alterations in epithelial cell polarity during endometrial receptivity: A systematic review. Front. Endocrinol. 2020, 11, 596324. [Google Scholar] [CrossRef] [PubMed]
  23. Egbase, P.E.; al-Sharhan, M.; al-Othman, S.; al-Mutawa, M.; Udo, E.E.; Grudzinskas, J.G. Incidence of microbial growth from the tip of the embryo transfer catheter after embryo transfer in relation to clinical pregnancy rate following in-vitro fertilization and embryo transfer. Hum. Reprod. 1996, 11, 1687–1689. [Google Scholar] [CrossRef] [PubMed]
  24. Swidsinski, A.; Loening-Baucke, V.; Mendling, W.; Dörffel, Y.; Schilling, J.; Halwani, Z.; Jiang, X.F.; Verstraelen, H.; Swidsinski, S. Infection through structured polymicrobial Gardnerella biofilms (StPM-GB). Histol. Histopathol. 2014, 29, 567–587. [Google Scholar] [PubMed]
  25. Edgell, T.A.; Evans, J.; Lazzaro, L.; Boyes, K.; Sridhar, M.; Catt, S.; Rombauts, L.J.F.; Vollenhoven, B.J.; Salamonsen, L.A. Assessment of potential biomarkers of pre-receptive and receptive endometrium in uterine fluid and a functional evaluation of the potential role of CSF3 in fertility. Cytokine 2018, 111, 222–229. [Google Scholar] [CrossRef]
  26. Yin, Y.; Wang, A.; Feng, L.; Wang, Y.; Zhang, H.; Zhang, I.; Bany, B.M.; Ma, L. Heparan Sulfate Proteoglycan Sulfation Regulates Uterine Differentiation and Signaling During Embryo Implantation. Endocrinology 2018, 159, 2459–2472. [Google Scholar] [CrossRef]
  27. Ni, N.; Gao, Y.; Fang, X.; Melgar, M.; Vincent, D.F.; Lydon, J.P.; Bartholin, L.; Li, Q. Glandular defects in the mouse uterus with sustained activation of TGF-beta signaling is associated with altered differentiation of endometrial stromal cells and formation of stromal compartment. PLoS ONE 2018, 13, e0209417. [Google Scholar] [CrossRef]
  28. Hultmark, D.; Steiner, H.; Rasmuson, T.; Boman, H.G. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur. J. Biochem. 1980, 106, 7–16. [Google Scholar] [CrossRef]
  29. Ganz, T.; Selsted, M.E.; Szklarek, D.; Harwig, S.S.; Daher, K.; Bainton, D.F.; Lehrer, R.I. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Investig. 1985, 76, 1427–1435. [Google Scholar] [CrossRef]
  30. Dlozi, P.N.; Gladchuk, A.; Crutchley, R.D.; Keuler, N.; Coetzee, R.; Dube, A. Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes. Biomed. Pharmacother. 2022, 151, 113189. [Google Scholar] [CrossRef]
  31. Solanki, S.S.; Singh, P.; Kashyap, P.; Sansi, M.S.; Ali, S.A. Promising role of defensins peptides as therapeutics to combat against viral infection. Microb. Pathog. 2021, 155, 104930. [Google Scholar] [CrossRef] [PubMed]
  32. Cicinelli, E.; Vitagliano, A.; Loizzi, V.; De Ziegler, D.; Fanelli, M.; Bettocchi, S.; Nardelli, C.; Trojano, G.; Cicinelli, R.; Minervini, C.F.; et al. Altered gene expression encoding cytochines, grow factors and cell cycle regulators in the endometrium of women with chronic endometritis. Diagnostics 2021, 11, 471. [Google Scholar] [CrossRef] [PubMed]
Table 1. Microbial concordance in the endometrium and in the vagina.
Table 1. Microbial concordance in the endometrium and in the vagina.
MicroorganismEndometriumVaginaConcordance
(K, %; a/b)
Bifidobacterium spp.111536.8%; 7/12
Gardnerella vaginalis233033.3%; 13/26
Mycoplasma hominis2233.3%; 1/2
Lactobacillus spp.271528.1%; 9/23
HPV10926.7%; 4/11
Enterobacteriaceae spp.122023.1%; 6/20
Bacteroides spp., Porphyromonas spp., Prevotella spp.222321.6%; 8/29
Enterococcus spp.111617.4%; 4/19
Mobiluncus spp., Corynebacterium spp.498.3%; 1/11
Streptococcus spp.777.7%; 1/12
Sneathia spp., Leptotrichia spp., Fusobacterium spp.21315.4%; 2/11
Atopobium vaginae10713.3%; 2/13
Peptostreptococcus spp.71913.0%; 3/20
Megasphaera spp., Velionella spp.61411.8%; 2/15
Clostridium spp., Lachnobacterium spp.3127.1%; 1/13
Staphylococcus spp.070%; 0/7
Streptococcus agalactiae420%; 0/6
Candida spp.1110%; 0/12
Ureaplasma parvum260%; 0/8
Haemophilus spp.010%; 0/1
Anaerococcus spp.330%; 0/6
Table 2. Endometrial TGFβ1, bFGF2, and DEFa1 concentrations in the investigated groups.
Table 2. Endometrial TGFβ1, bFGF2, and DEFa1 concentrations in the investigated groups.
ParameterInfertile GroupFertile GroupUWZp
bFGF2,
pg/mL
19.931
[16.18; 40.65]
48.8
[40.0; 50.83]
159.52304.5−3.79<0.0001
TGFβ1,
pg/mL
5.28
[2.93; 8.4]
8.02
[6.008; 10.6]
252.02397.0−2.610.009
DEFa1,
pg/mL
0.746
[0.532; 1.159]
0.615
[0.493; 0.672]
297.5402.5−2.0220.042
U—Mann–Whitney U test, W—Wilcoxon rank-sum test. Data are presented as the median and interquartile range (25th and 75th percentile). bFGF2—basic fibroblast growth factor, TGFβ1—transforming growth factor beta, DEFa1—α-defensin.
Table 3. Endometrial TGFβ1, bFGF2, and DEFa1 concentrations among patients with idiopathic infertility in relation to microorganisms verified.
Table 3. Endometrial TGFβ1, bFGF2, and DEFa1 concentrations among patients with idiopathic infertility in relation to microorganisms verified.
Microorganism/
Positive History
Presence in Endometrium/
Positive History
bFGF2,
pg/mL
TGFβ1,
pg/mL
DEFa1,
pg/mL
Microbiological data
Lactobacillus spp.Yes
(n = 27)
20.3 [16.81; 42.55]5.28 [2.2; 9.23]0.83 [0.63; 1.23]
No
(n = 38)
19.71 [17; 25.41]5.13 [3.22; 7.95]0.69 [0.52; 0.92]
stat.t = 1.0724
p = 0.261
t = 1.2
p = 0.234
t = 1.818
p = 0.068
Peptostreptococcus spp.Yes
(n = 7)
40.9 [19.49; 42.6]5.86 [5.35; 7.21]0.653 [0.588; 0.687]
No
(n = 58)
19.71 [15.52; 25.79]4.76 [2.83; 8.5]0.75 [0.53; 1.12]
stat.U = 134.5
p = 0.149
t = 0.198
p = 0.797
U = 137.5
p = 0.171
F = 1562.7
p = 0.0011
HPVYes
(n = 10)
19.34 [12.99; 29.66]5.57 [4.73; 7.67]0.97 [0.54; 4.36]
no
(n = 55)
19.93 [17.16; 40.65]5.12 [2.86; 8.63]0.75 [0.55; 1.01]
stat.U = 232.5
p = 0.44
t = 1.75
p = 0.086
t = 3.132
p = 0.003
Anamnestic data
Recurrent genital HSV infectionYes
(n = 21)
19.49 [15.52; 42.59]5.42 [2.05; 9.8]1.27 [0.9; 5.42]
No
(n = 44)
20.12 [17.32; 38.45]5.205 [3.22; 8.18]0.65 [0.49; 0.77]
stat.t = 0.573
p = 0.57
U = 460.5
p = 0.989;
F = 9.6
p = 0.028
t = 4.255
p = 0.008
Ectopic pregnancyYes
(n = 8)
8.77 [5.4; 19.184]0.81 [0; 4.21]0.453 [0.256; 0.73]
No
(n = 57)
20.52 [18.11; 42]5.28 [3.22; 8.2]0.75 [0.59; 1.15]
stat.U = 80.5
p = 0.002
U = 71.5
p = 0.0012
U = 93
p = 0.005
U—Mann–Whitney U test, F—Wilcoxon rank-sum test, F—Fisher’s exact test. bFGF2—basic fibroblast growth factor, TGFβ1—transforming growth factor beta, DEFa1—α-defensin.
Table 4. Composition of endometrial microbiota and biomarker concentrations in patients with pregnancy achieved during the follow-up period.
Table 4. Composition of endometrial microbiota and biomarker concentrations in patients with pregnancy achieved during the follow-up period.
MicroorganismPatient’s Identification Number
614172342555662
Lactobacillus spp.+ ++++
Bifidobacterium spp. + +
Gardnerella vaginalis+ ++ +
Atopobium vaginae+ + +
Bacteroides spp., Porphyromonas spp., Prevotella spp. + +
Enterobacteriaceae spp. +++ + +
Enterococcus spp. +
Megasphaera spp., Velionella spp. +
Peptostreptococcus spp. +
Streptococcus spp. + ++ +
Anaerococcus spp. +
Human papillomavirus (HPV)+
Immune biomarkers
bFGF2, pg/mL3.3735.39715.5225.410.6756.07118.735.399
TGFβ1, pg/mL49.192.0528.653.0792.34506.30
DEFa1, pg/mL16.120.6652.0980.99600.250.4860.425
Number of microorganisms423521013
Table 5. Clinical and social parameters in groups investigated.
Table 5. Clinical and social parameters in groups investigated.
ParameterInfertile GroupFertile Group
Number of patients, n6514
Age [min; max], yo25–3725–38
Median [25th percentile; 75th percentile], yo33 [28; 35]34 [29; 35]
Education:
Higher education27 (41.5%)14 (100%)
Intermediate vocational education21 (32.3%)-
Secondary-level education17 (26.2%)-
Social status:
Married32 (49.2%)8 (57.1%)
Single33 (50.8%)6 (42.9%)
Body mass index (kg/m2)
18.5–19.99 (13.8%)-
20.0–25.029 (44.6%)10 (71.4%)
25.0–29.926 (40.0%)4 (28.6%)
Smoking:
Yes22 (33.8%)3 (21.4%)
No43 (66.2%)11 (78.6%)
Table 6. Parameters of obstetric and gynecological history in the investigated groups.
Table 6. Parameters of obstetric and gynecological history in the investigated groups.
ParameterInfertile GroupFertile Group
Number of deliveries
1
2
65 (100%)
43 (66.2%)
22 (33.8%)
14 (100%)
0
14 (100%)
History of miscarriage followed by:
uterine abrasion
medication-induced abortion
45 (69.2%)
34 (52.3%)
11 (16.9%)
0
0
0
Ectopic pregnancy followed by:
laparoscopic surgery
laparotomy
8 (12.3%)
7 (10.8%)
1 (1.5%)
0
0
0
History of IVF failures8 (12.3%)0
History of surgical interventions
hysteroscopy
laparoscopy
49 (75.4%)
38 (58.5%)
15 (23.1%)
0
0
0
History of viral infections
recurrent herpes simplex virus infection
history of human papillomavirus
27 (41.5%)
21 (32.3%)
8 (12.3%)
0
0
0
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tapilskaya, N.I.; Savicheva, A.M.; Shalepo, K.V.; Budilovskaya, O.V.; Gzgzyan, A.M.; Bespalova, O.N.; Khusnutdinova, T.A.; Krysanova, A.A.; Obedkova, K.V.; Safarian, G.K. Local Immune Biomarker Expression Depending on the Uterine Microbiota in Patients with Idiopathic Infertility. Int. J. Mol. Sci. 2023, 24, 7572. https://doi.org/10.3390/ijms24087572

AMA Style

Tapilskaya NI, Savicheva AM, Shalepo KV, Budilovskaya OV, Gzgzyan AM, Bespalova ON, Khusnutdinova TA, Krysanova AA, Obedkova KV, Safarian GK. Local Immune Biomarker Expression Depending on the Uterine Microbiota in Patients with Idiopathic Infertility. International Journal of Molecular Sciences. 2023; 24(8):7572. https://doi.org/10.3390/ijms24087572

Chicago/Turabian Style

Tapilskaya, Natalya I., Alevtina M. Savicheva, Kira V. Shalepo, Olga V. Budilovskaya, Aleksandr M. Gzgzyan, Olesya N. Bespalova, Tatiana A. Khusnutdinova, Anna A. Krysanova, Kseniia V. Obedkova, and Galina Kh. Safarian. 2023. "Local Immune Biomarker Expression Depending on the Uterine Microbiota in Patients with Idiopathic Infertility" International Journal of Molecular Sciences 24, no. 8: 7572. https://doi.org/10.3390/ijms24087572

APA Style

Tapilskaya, N. I., Savicheva, A. M., Shalepo, K. V., Budilovskaya, O. V., Gzgzyan, A. M., Bespalova, O. N., Khusnutdinova, T. A., Krysanova, A. A., Obedkova, K. V., & Safarian, G. K. (2023). Local Immune Biomarker Expression Depending on the Uterine Microbiota in Patients with Idiopathic Infertility. International Journal of Molecular Sciences, 24(8), 7572. https://doi.org/10.3390/ijms24087572

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop